Veradermics, Inc
MANEdata completeness 75%2 fiscal years on fileData notes: no data for concept 'revenue'; no data for concept 'totalDebt'; no data for concept 'investmentsAtFairValue'; no data for concept 'netInvestmentIncome'; no data for concept 'depreciationAmortization'; no data for concept 'gainsOnRealEstateSales'; no data for concept 'realEstateImpairment'; no data for concept 'dividendsPaid'; no data for concept 'interestExpense'
| Figure | FY 2024 | FY 2025 |
|---|---|---|
| Revenue | — | — |
| Net income | −$26.5M1 | −$70M1 |
| Operating cash flow | −$23.7M2 | −$71.6M2 |
| Capital expenditure | $03 | $24,0003 |
| Free cash flow (derived) | −$23.7M2 | −$71.6M2 |
| Total debt | — | — |
| Cash & equivalents | $53.1M4 | $21.8M4 |
| Diluted shares | 736,933 | 744,991 |
Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom).
10 shares is a claim on −$1,624.37 of net worth that earned you −$939.54 and generated −$961.43 of cash last year.
Not enough data in the filings for a return-on-capital reading.
seeing a moat in the numbers →Share count is roughly flat over 2 years — little dilution, little buyback.
reading capital allocation →Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.
Different models answer different questions — which to trust when →
- 10-K · period ending 2024-12-31 · accession 0001827635-26-000013 (NetIncomeLoss)
- 10-K · period ending 2024-12-31 · accession 0001827635-26-000013 (NetCashProvidedByUsedInOperatingActivities)
- 10-K · period ending 2024-12-31 · accession 0001827635-26-000013 (PaymentsToAcquirePropertyPlantAndEquipment)
- 10-K · period ending 2024-12-31 · accession 0001827635-26-000013 (CashAndCashEquivalentsAtCarryingValue)